NEW YORK – Roche subsidiary Foundation Medicine announced Tuesday that it will launch two new next-generation sequencing-based germline tests in the US through a partnership with Fulgent Genetics.
FoundationOne Germline will analyze 50 genes associated with hereditary cancers, while FoundationOne Germline More will analyze 154 genes, including well-established cancer-related genes and candidate genes with emerging evidence of association with cancer risk, Foundation said in a statement. FoundationOne Germline More is intended for patients with complex clinical presentations and family histories that require broader genetic analysis.
Both assays utilize Fulgent's proprietary technology platform and analyze single-nucleotide and copy number variations.
"The results from our germline tests can help explain why a patient initially developed cancer and provide insights into potential increased future cancer risks, delivering important new value to the healthcare providers and patients we serve," Foundation Medicine Chief Commercial Officer Annie Murphy said in a statement.
Clinicians will be able to add both tests to any Foundation Medicine comprehensive genomic profiling test through Foundation's portal beginning Feb. 28.